                </a></li></ul></div><p><strong>Figure 6.  <span>Major changes after 16-months after activation of hVEGF-A<sub>165</sub> expression.</span></strong></p><a id="article1.body1.sec2.sec2.fig2.caption1.p1" name="article1.body1.sec2.sec2.fig2.caption1.p1"></a><p>A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p2" name="article1.body1.sec2.sec2.fig2.caption1.p2"></a><p>B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p3" name="article1.body1.sec2.sec2.fig2.caption1.p3"></a><p>C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p4" name="article1.body1.sec2.sec2.fig2.caption1.p4"></a><p>D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p5" name="article1.body1.sec2.sec2.fig2.caption1.p5"></a><p>E. Macroscopical changes in paratubarian area (microscopical sections in L–N).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p6" name="article1.body1.sec2.sec2.fig2.caption1.p6"></a><p>F. Cavernous hemangioma featuring focal hyalinization.</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p7" name="article1.body1.sec2.sec2.fig2.caption1.p7"></a><p>G. The same tumor mass area with higher magnification (haematoxylin-eosin).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p8" name="article1.body1.sec2.sec2.fig2.caption1.p8"></a><p>H. Weak focal hVEGF-A<sub>165</sub> immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells.</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p9" name="article1.body1.sec2.sec2.fig2.caption1.p9"></a><p>I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining.</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p10" name="article1.body1.sec2.sec2.fig2.caption1.p10"></a><p>I. Hematoxylin-eosin. (an arrow points to an area shown in K)</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p11" name="article1.body1.sec2.sec2.fig2.caption1.p11"></a><p>J. CD34 immunostaining.</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p12" name="article1.body1.sec2.sec2.fig2.caption1.p12"></a><p>K. The same area as in I with higher magnification (stained with Masson Trichrom).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p13" name="article1.body1.sec2.sec2.fig2.caption1.p13"></a><p>Asterix in I and J indicate the same area.</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p14" name="article1.body1.sec2.sec2.fig2.caption1.p14"></a><p>L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A<sub>165</sub> immunopositivity shown in N. (hVEGF-A<sub>165</sub> immunostaining).</p>
<a id="article1.body1.sec2.sec2.fig2.caption1.p15" name="article1.body1.sec2.sec2.fig2.caption1.p15"></a><p>Bar<strong>:</strong> F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.</p>
